GlycoMimetics Management
Management criteria checks 4/4
GlycoMimetics' CEO is Harout Semerjian, appointed in Aug 2021, has a tenure of 2.58 years. total yearly compensation is $1.43M, comprised of 42.8% salary and 57.2% bonuses, including company stock and options. directly owns 0.039% of the company’s shares, worth $70.50K. The average tenure of the management team and the board of directors is 2.6 years and 7.5 years respectively.
Key information
Harout Semerjian
Chief executive officer
US$1.4m
Total compensation
CEO salary percentage | 42.8% |
CEO tenure | 2.6yrs |
CEO ownership | 0.04% |
Management average tenure | 2.6yrs |
Board average tenure | 7.5yrs |
Recent management updates
Recent updates
GlycoMimetics Can Become A Game Changer In Blood Cancers
Mar 21Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?
Mar 20GlycoMimetics: Drug Approval Is Not Coming In 2024, But The Hype Could Be Real
Jan 30Is GlycoMimetics (NASDAQ:GLYC) In A Good Position To Deliver On Growth Plans?
Nov 19Will GlycoMimetics (NASDAQ:GLYC) Spend Its Cash Wisely?
Jan 30Here's Why GlycoMimetics (NASDAQ:GLYC) Must Use Its Cash Wisely
Oct 06GlycoMimetics has a new Chief Medical Officer
Sep 06GlycoMimetics GAAP EPS of $0.25 beats by $0.53, revenue of $75K
Aug 03GlycoMimetics (NASDAQ:GLYC) Will Have To Spend Its Cash Wisely
Jun 04GlycoMimetics Positive Data For AML Therapy Increasingly Likely
Mar 16Here's Why We're Watching GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation
Nov 20We Think GlycoMimetics (NASDAQ:GLYC) Needs To Drive Business Growth Carefully
Aug 20GlycoMimetics says first patient dosed in investigator-sponsored mid-stage uproleselan study
May 26Here's Why It's Unlikely That GlycoMimetics, Inc.'s (NASDAQ:GLYC) CEO Will See A Pay Rise This Year
May 12GlycoMimetics EPS beats by $0.04
May 03Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation
Mar 26GlycoMimetics' (NASDAQ:GLYC) Shareholders Are Down 83% On Their Shares
Feb 19GlycoMimetics, Inc. (NASDAQ:GLYC) Insiders Increased Their Holdings
Jan 24How Much Did GlycoMimetics' (NASDAQ:GLYC) CEO Pocket Last Year?
Dec 28New data from GlycoMimetics highlights the efficacy Rivipansel in vaso-occlusive crisis in sickle cell disease
Dec 07Here's Why We're Not Too Worried About GlycoMimetics' (NASDAQ:GLYC) Cash Burn Situation
Dec 07The Investment Case For GlycoMimetics
Nov 17CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Sep 30 2023 | n/a | n/a | -US$38m |
Jun 30 2023 | n/a | n/a | -US$37m |
Mar 31 2023 | n/a | n/a | -US$42m |
Dec 31 2022 | US$1m | US$614k | -US$47m |
Sep 30 2022 | n/a | n/a | -US$54m |
Jun 30 2022 | n/a | n/a | -US$63m |
Mar 31 2022 | n/a | n/a | -US$64m |
Dec 31 2021 | US$3m | US$244k | -US$63m |
Compensation vs Market: Harout's total compensation ($USD1.43M) is about average for companies of similar size in the US market ($USD1.47M).
Compensation vs Earnings: Harout's compensation has been consistent with company performance over the past year.
CEO
Harout Semerjian (53 yo)
2.6yrs
Tenure
US$1,434,922
Compensation
Mr. Harout Semerjian serves as Chief Executive Officer, President & Director of GlycoMimetics, Inc., since August 6, 2021. He served as President and Chief Executive Officer of Immunomedics Inc. since Apri...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, President & Director | 2.6yrs | US$1.43m | 0.039% $ 70.5k | |
Co-Founder & Director | 21.2yrs | US$235.67k | 0.98% $ 1.8m | |
Senior VP & CFO | 12.2yrs | US$918.19k | 0.056% $ 101.2k | |
Vice President of Accounting | 5.2yrs | no data | no data | |
General Counsel & Company Secretary | 4.9yrs | no data | no data | |
Senior VP & Chief Commercial Officer | 2.1yrs | no data | 0.22% $ 391.9k | |
Senior VP & Chief Medical Officer | 1.5yrs | no data | 0.58% $ 1.1m | |
Senior VP & Chief Business Officer | 1.2yrs | no data | 0.25% $ 454.5k | |
Senior Vice President of Technical Operations | less than a year | no data | no data |
2.6yrs
Average Tenure
53yo
Average Age
Experienced Management: GLYC's management team is considered experienced (2.6 years average tenure).
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
CEO, President & Director | 2.6yrs | US$1.43m | 0.039% $ 70.5k | |
Co-Founder & Director | 21.2yrs | US$235.67k | 0.98% $ 1.8m | |
Independent Director | 8yrs | US$71.74k | 0.14% $ 263.0k | |
Independent Chairman of the Board | 10yrs | US$91.24k | 0.038% $ 69.5k | |
Independent Director | 7yrs | US$53.74k | 0.057% $ 103.6k | |
Independent Director | 5.3yrs | US$64.24k | 0.0081% $ 14.8k | |
Independent Director | 6.8yrs | US$58.24k | 0.091% $ 165.3k | |
Independent Director | 9.7yrs | US$64.24k | 0.049% $ 89.5k |
7.5yrs
Average Tenure
64yo
Average Age
Experienced Board: GLYC's board of directors are considered experienced (7.5 years average tenure).